罗格列酮联合洛沙坦对糖尿病肾病大鼠足细胞的协同保护作用  

The protective effect of the combination of rosiglitazone and losartan on the podocytes of diabetic nephropathy rats

作　　者：陈立平[1] 周巧玲[1] 彭卫生[1] 刘抗寒[1] 欧阳春[1] 吴晓英[2] 尹红玲[3] 

机构地区：[1]中南大学湘雅医院肾内科,长沙市410008 [2]中南大学湘雅医院电镜室,长沙市410008 [3]中南大学湘雅医院病理科,长沙市410008

出　　处：《实用医学杂志》2007年第8期1124-1126,共3页The Journal of Practical Medicine

基　　金：湖南省自然科学基金课题(编号:05JJ30177)

摘　　要：目的:探讨罗格列酮联合洛沙坦对糖尿病肾病(DN)大鼠足细胞的协同保护作用。方法:制备DN大鼠模型,将动物随机分为DN模型组、罗格列酮干预组、洛沙坦干预组及罗格列酮联合洛沙坦干预组,另设正常对照组。8周后观察尿蛋白排泄量,用免疫组化、RT-PCR方法检测肾皮质nephrin、podocin蛋白及mRNA表达,用透射电镜检测足细胞超微结构变化。结果:(1)各干预组DN鼠尿蛋白排泄均减少。(2)联合干预组对足细胞超微结构及nephrin、podocin下调的改善作用优于单药干预组。结论:罗格列酮与洛沙坦联合用药对DN大鼠肾脏保护作用优于单种药物治疗,其机制部分与改善足细胞超微结构及上调nephrin、podocin表达有关。Objective To investigate the protective effect of the combination of rosiglitazone and losartan on the podocytes of diabetic nephropathy （DN） rats. Methods A rat model of DN was established. The DN rats were then randomized to DN model group, rosiglitazone-treated group, losartan-treated group, or combined treatment group. 24 h urine protein excretion was determined, the ultrastructure of pedocytes was measured under electron microscopy, and the expressions of nephrin and pedocin were detected by immunohistochemisty and RT-PCR 8 weeks after treatment. Results A decrease in 24 h urine protein excretion occurred in all treatment groups. A better improvement on the ultrastructure of the podcytes and on the downregulation of nephrin and pedocin expressions developed in the combined treatment group than in rosiglitazone- or losartan-treated group. Conclusion The protective effect of rosiglitazone combined with losartan on the kidney of the DN rats is superior to the agents used separately, whose mechanism may be partly related with the upregulation of the expressions of nephrin and podocin, and with the improvement of the uhrastructure of podocytes.

关 键 词：糖尿病肾病 噻唑烷二酮类 洛沙坦 大鼠 足细胞 

分 类 号：R587.2[医药卫生—内分泌]